Sutro Biopharma Inc diskutieren
Sutro Biopharma Inc
WKN: A2N6SG / Symbol: STRO / Name: Sutro Biopharma / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
0,62 €
-8,51 %
Sutro Biopharma, Inc. (NASDAQ: STRO) had its price target lowered by analysts at Truist Financial Co. from $18.00 to $15.00. They now have a "buy" rating on the stock.
Ratings data for STRO provided by MarketBeat
Sutro Biopharma, Inc. (NASDAQ: STRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Ratings data for STRO provided by MarketBeat
Sutro Biopharma, Inc. (NASDAQ: STRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Ratings data for STRO provided by MarketBeat
Sutro Biopharma, Inc. (NASDAQ: STRO) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $11.00 price target on the stock.
Ratings data for STRO provided by MarketBeat
Sutro Biopharma, Inc. (NASDAQ: STRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Ratings data for STRO provided by MarketBeat
Sutro Biopharma, Inc. (NASDAQ: STRO) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $8.00 price target on the stock.
Ratings data for STRO provided by MarketBeat
Sutro Biopharma, Inc. (NASDAQ: STRO) was downgraded by analysts at Bank of America Co. from a "buy" rating to an "underperform" rating. They now have a $1.00 price target on the stock, down previously from $11.00.
Ratings data for STRO provided by MarketBeat
Sutro Biopharma, Inc. (NASDAQ: STRO) had its price target lowered by analysts at Bank of America Co. from $1.00 to $0.80. They now have an "underperform" rating on the stock.
Ratings data for STRO provided by MarketBeat
Sutro Biopharma, Inc. (NASDAQ: STRO) was upgraded by analysts at Piper Sandler from a "neutral" rating to an "overweight" rating. They now have a $2.00 price target on the stock.
Ratings data for STRO provided by MarketBeat
Sutro Biopharma (NASDAQ:STRO) had its "buy" rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft.
Ratings data for STRO provided by MarketBeat
Sutro Biopharma (STRO) was upgraded by Wells Fargo & Company from "equal weight" to "overweight". They now have a $27.00 price target on the stock, up from $8.00.
Ratings data for STRO provided by MarketBeat
Sutro Biopharma (STRO) was upgraded by HC Wainwright from "neutral" to "buy". They now have a $28.00 price target on the stock, up from $10.00.
Ratings data for STRO provided by MarketBeat
Sutro Biopharma (STRO) had its price target raised by Deutsche Bank Aktiengesellschaft from $51.00 to $55.00. They now have a "buy" rating on the stock.
Ratings data for STRO provided by MarketBeat
Sutro Biopharma (STRO) is now covered by Leerink Partners. They set an "outperform" rating and a $38.00 price target on the stock.
Ratings data for STRO provided by MarketBeat
Sutro Biopharma (STRO) was given a new $50.00 price target by Mizuho. They now have an "outperform" rating on the stock.
Ratings data for STRO provided by MarketBeat
Sutro Biopharma (STRO) was upgraded by Wedbush from "outperform" to "outperform".
Ratings data for STRO provided by MarketBeat
Sutro Biopharma (STRO) had its price target raised by HC Wainwright from $28.00 to $50.00. They now have a "buy" rating on the stock.
Ratings data for STRO provided by MarketBeat
Neueste Beiträge
Fearnley_Fonds in Tidewater Inc. diskutieren